Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, has announced the pricing of its underwritten public offering of 13,636,364 shares of common stock at a public offering price of US$22.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by […]
The post Latham & Watkins Advises Revolution Medicines in its US$300.0 Million Public Offering of Common Stock appeared first on Legal Desire.